|
|---|
| | General | |
|---|
| Usage | |
|---|
| Variants | |
|---|
| Effects | |
|---|
| Culture | |
|---|
| Organizations | |
|---|
| Demographics | |
|---|
| Politics | | General | |
|---|
Major legal
reforms | |
|---|
Politicians
and parties | |
|---|
| Legal cases | |
|---|
|
|---|
| Related | |
|---|
|
|
|---|
Phytocannabinoids
(comparison) | | Cannabibutols | |
|---|
| Cannabichromenes | |
|---|
| Cannabicyclols | |
|---|
| Cannabidiols | |
|---|
| Cannabielsoins | |
|---|
| Cannabigerols | |
|---|
| Cannabiphorols | |
|---|
| Cannabinols | |
|---|
| Cannabitriols | |
|---|
| Cannabivarins | |
|---|
| Delta-3-tetrahydrocannabinols | |
|---|
| Delta-4-tetrahydrocannabinols | |
|---|
| Delta-7-tetrahydrocannabinols | |
|---|
| Delta-8-tetrahydrocannabinols | |
|---|
| Delta-9-tetrahydrocannabinols | |
|---|
| Delta-10-Tetrahydrocannabinols | |
|---|
| Delta-11-Tetrahydrocannabinols | |
|---|
| Miscellaneous cannabinoids | |
|---|
| Active metabolites | |
|---|
|
|---|
| Endocannabinoids | |
|---|
Synthetic
cannabinoid
receptor
agonists /
neocannabinoids | Classical cannabinoids
(dibenzopyrans) | |
|---|
Non-classical
cannabinoids | |
|---|
| Adamantoylindoles | |
|---|
| Benzimidazoles | |
|---|
| Benzoylindoles | |
|---|
| Cyclohexylphenols | |
|---|
| Eicosanoids | |
|---|
Indazole-3-
carboxamides | |
|---|
| Indole-3-carboxamides | |
|---|
| Indole-3-carboxylates | |
|---|
| Naphthoylindazoles | |
|---|
| Naphthoylindoles | |
|---|
| Naphthoylpyrroles | |
|---|
| Naphthylmethylindenes | |
|---|
| Naphthylmethylindoles | |
|---|
| Phenylacetylindoles | |
|---|
| Pyrazolecarboxamides | |
|---|
Tetramethylcyclo-
propanoylindazoles | |
|---|
Tetramethylcyclo-
propanoylindoles | |
|---|
| Others | |
|---|
|
|---|
| Allosteric CBRTooltip Cannabinoid receptor ligands | |
|---|
Endocannabinoid
enhancers
(inactivation inhibitors) | |
|---|
Anticannabinoids
(antagonists/inverse
agonists/antibodies) | |
|---|
|
|
|---|
Receptor
(ligands) | | CB1Tooltip Cannabinoid receptor type 1 | Agonists
(abridged,
full list) | |
|---|
| Inverse agonists | |
|---|
| Antagonists | |
|---|
|
|---|
| CB2Tooltip Cannabinoid receptor type 2 | | Agonists |
- 2-AG
- 2-AGE (noladin ether)
- 3,3'-Diindolylmethane
- 4-O-Methylhonokiol
- α-Amyrin · β-Amyrin
- A-796,260
- A-834,735
- A-836,339
- AM-1172
- AM-1221
- AM-1235
- AM-1241
- AM-2232
- Anandamide
- AZ-11713908
- Cannabinol
- Caryophyllene
- CB-13
- CBS-0550
- CP 55,940
- GW-405,833 (L-768,242)
- GW-842,166X
- HU-308
- JTE 7-31
- JWH-007
- JWH-015
- JWH-018
- JWH-73
- JWH-133
- L-759,633
- L-759,656
- Lenabasum (anabasum)
- Magnolol
- MDA-19
- Nabitan
- NADA
- Olorinab (APD-371)
- PF-03550096
- S-444,823
- SER-601
- Serinolamide A
- UR-144
- Tedalinab
- THC (dronabinol)
- THCV
- Tetrahydromagnolol
- Virodhamine
|
|---|
| Antagonists | |
|---|
|
|---|
NAGly
(GPR18) | |
|---|
| GPR55 | |
|---|
| GPR119 | |
|---|
|
|---|
Transporter
(modulators) | | eCBTsTooltip Endocannabinoid transporter | |
|---|
|
|---|
Enzyme
(modulators) | |
|---|
| Others |
- Others: 2-PG (directly potentiates activity of 2-AG at CB1 receptor)
- ARN-272 (FAAH-like anandamide transporter inhibitor)
|
|---|
|
|
|---|
- μ-Opioid receptor agonists (opioids) (e.g., morphine, heroin, hydrocodone, oxycodone, opium, kratom)
- α2δ subunit-containing voltage-dependent calcium channels blockers (gabapentinoids) (e.g., gabapentin, pregabalin, phenibut)
- AMPA receptor antagonists (e.g., perampanel)
- CB1 receptor agonists (cannabinoids) (e.g., THC, cannabis)
- Dopamine receptor agonists (e.g., levodopa)
- Dopamine releasing agents (e.g., amphetamine, methamphetamine, MDMA, mephedrone)
- Dopamine reuptake inhibitors (e.g., cocaine, methylphenidate)
- GABAA receptor positive allosteric modulators (e.g., barbiturates, benzodiazepines, carbamates, ethanol (alcohol) (alcoholic drink), inhalants, nonbenzodiazepines, quinazolinones)
- GHB (sodium oxybate) and analogues
- Glucocorticoids (corticosteroids) (e.g., dexamethasone, prednisone)
- nACh receptor agonists (e.g., nicotine, tobacco, arecoline, areca nut)
- Nitric oxide prodrugs (e.g., alkyl nitrites (poppers))
- NMDA receptor antagonists (e.g., DXM, ketamine, methoxetamine, nitrous oxide, phencyclidine, inhalants)
- Orexin receptor antagonists (e.g., suvorexant)
| |
|
|---|
| | Legality of drug use |
|---|
| International | |
|---|
| State level | |
|---|
Drug policy
by country | |
|---|
| Drug legality | |
|---|
| Other | |
|---|
|
| Other |
|---|
Drug
production
and trade | Drug
production | |
|---|
| Drug trade | |
|---|
|
|---|
Issues with
drug use | |
|---|
| Harm reduction | |
|---|
Countries by
drug use | |
|---|
|
|
|
